The IKBIP Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for the disruption of the IKBIP gene (IKBKB-interacting protein) in the human hepatocellular carcinoma cell line SK-HEP-1. This gene-edited pool provides a loss-of-function model system to investigate the regulatory roles of IKBIP in NF-??B signaling, apoptosis, and p53-dependent stress responses. Unlike clonal isolates, the polyclonal population captures a spectrum of knockout variants, enabling robust assessment of IKBIP function in a heterogeneous cell background. The product is supplied as a vial of cryopreserved cells and is intended for fundamental research applications in cancer biology, signal transduction, and drug development.
The parental SK-HEP-1 cell line is an immortalized human epithelial line originally derived from the ascitic fluid of a patient with liver adenocarcinoma. It is widely employed as an in vitro model of hepatocellular carcinoma, particularly in studies of tumor cell migration, invasion, and metastasis. SK-HEP-1 cells retain key signaling pathways relevant to hepatic malignancy and enable functional interrogation of oncogenic and tumor-suppressive networks, including NF-??B and p53. Their adherent growth characteristics and compatibility with standard culture conditions make them a practical platform for genetic manipulation and downstream molecular and pharmacological assays.
IKBIP is a p53-inducible protein that functions as a critical modulator of the NF-??B transcription factor pathway. Mechanistically, IKBIP directly interacts with IKBKB (IKK-??), a central kinase within the I??B kinase complex, and attenuates NF-??B-mediated gene expression. By dampening NF-??B activity, IKBIP promotes pro-apoptotic signaling and sensitizes cells to cell death stimuli. IKBIP expression is upregulated by TP53 (p53) upon genotoxic stress, and its downstream effects include suppression of NF-??B target genes and facilitation of caspase activation. Key molecular partners include IKBKB, IKBKG (NEMO), RIPK1, p53, and caspase-3, placing IKBIP at the intersection of DNA damage response and inflammatory signaling.
In hepatocellular carcinoma, NF-??B is frequently constitutively active and contributes to tumor cell survival, proliferation, and chemoresistance. Disruption of IKBIP in SK-HEP-1 cells is predicted to relieve this negative regulation, leading to elevated NF-??B transcriptional activity and enhanced expression of anti-apoptotic factors. Consequently, the IKBIP knockout model may exhibit increased resistance to apoptosis-inducing agents, such as TNF-?? or genotoxic drugs like doxorubicin, providing a useful tool to dissect the interplay between p53 and NF-??B pathways in liver cancer. This polyclonal knockout population is especially valuable for studying the functional consequences of IKBIP loss without the confounding effects of clonal selection.
Researchers can employ this knockout model in a wide array of investigations, including quantitative assessment of NF-??B activity via luciferase reporter assays, Western blot analysis of pathway components (e.g., phospho-IKK-??, I??B??, p65), and apoptosis profiling using annexin V/PI staining or caspase-3/7 activity measurements. The cells are also suited for co-immunoprecipitation studies to examine IKK complex formation and for drug sensitivity screens to identify IKK-?? modulators or agents that exploit p53 status. Additional applications encompass RT-qPCR-based monitoring of p53 target genes and immunofluorescence imaging of NF-??B nuclear translocation. For further details regarding availability and technical specifications, please contact Ascent Research.
